CORONA vs JSLL: Stock Comparison

CORONA REMEDIES vs JEENA SIKHO LIFECAREUpdated 17 Sept 26, 12:19 PM ISTNSE & company filings

CORONA REMEDIES is the larger company by market capitalisation. CORONA REMEDIES shows a higher dividend yield, while JEENA SIKHO LIFECARE shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

CORONA leads 3; JSLL leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

CORONAJSLL

Valuation lens

What price are you paying?

Market CapContext only
₹13,087 Cr
₹6,195 Cr
P/E RatioJSLL has the lower reading
66.97x
26.04x
P/B RatioJSLL has the lower reading
17.84x
13.19x
EPSCORONA has the higher reading
₹9.83
₹5.28
Book ValueContext only
₹122.12
₹37.57
Dividend YieldCORONA has the higher reading
0.46%
0.22%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
CORONA is the larger company
₹13,087 Cr vs ₹6,195 Cr
P/E Ratio
JSLL has a lower P/E
26.04x vs 66.97x
P/B Ratio
JSLL has a lower P/B
13.19x vs 17.84x
EPS
CORONA has higher earnings per share
₹9.83 vs ₹5.28
Dividend Yield
CORONA has a higher dividend yield
0.46% vs 0.22%
Revenue Growth (TTM YoY)
JSLL has faster revenue growth
54.8% vs 0%
EPS Growth (TTM YoY)
JSLL has faster EPS growth
77.5% vs 0%
Qtr Profit Growth
CORONA has stronger quarterly profit growth
-0.02% vs -0.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCORONAJSLL
SectorHealthcare
IndustryPharmaceuticals

Price

MetricCORONAJSLL
Live Price₹2,151.1₹497.55
Day Change0.35%0.1%
Volume6,30679,335
52-Week High₹2,292.4₹849.5
52-Week Low₹1,336.6₹485.1
Distance from 52W High-6.16%-41.43%

Valuation

MetricCORONAJSLL
Market Cap₹13,087 Cr₹6,195 Cr
P/E Ratio66.97x26.04x
P/B Ratio17.84x13.19x
EPS₹9.83₹5.28
Book Value₹122.12₹37.57
Dividend Yield0.46%0.22%

Growth

MetricCORONAJSLL
Revenue Growth (TTM YoY)0%54.8%
EPS Growth (TTM YoY)0%77.5%
Qtr Sales Growth0%0%
Qtr Profit Growth-0.02%-0.3%

Profitability & Leverage

MetricCORONAJSLL
ROE24.28%47.48%
ROCE20.94%51.27%
Net Margin13.19%27.68%
Operating Margin15.89%38.71%
Debt to Equity0.19x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCORONAJSLL
Promoter Holding69%63.62%
FII Holding3.63% 1.38 pp4.78% 1.39 pp
DII Holding12.9% 5.88 pp0.36% 0.1 pp
Public Holding14.48% 7.26 pp31.23% 1.47 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CORONA REMEDIES and JEENA SIKHO LIFECARE.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.